As FDA labeling evolves, telehealth scales, and demand for customized hormone therapy grows, pharmacies and outsourcing facilities face new expectations. The next era of menopause care will depend on infrastructure capable of supporting consistent, well-coordinated, personalized hormone therapy services at scale. Here’s what every 503A pharmacy, 503B outsourcing facility, and telehealth organization needs to anticipate next.
Read MorePrescribers and regulators may question the clinical need of compounded bioidentical hormone therapies (cBHT) and how they differ from FDA approved drug products. The argument for compounding identical hormones is no longer useful, given the number of estradiol products available in topical forms, but the differences between those and what compounders offer are still unique and significant.
Read MoreFDA-approved menopausal hormone therapy (MHT) products have seen a dramatic decrease in prescribing practices over the past decade, meanwhile, custom-compounded hormone therapy (CHT) preparations have become more popular.
Read More
